{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:52:19Z","timestamp":1770972739760,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["\u201c5 per 1000\u201d funds for healthcare research"],"award-info":[{"award-number":["\u201c5 per 1000\u201d funds for healthcare research"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18673-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:16:04Z","timestamp":1763478964000},"page":"2255-2266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0\/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Gabriele","family":"Martelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Barretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Muzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Listorti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pilotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Osio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Bonfili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Secondo","family":"Folli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Scaperrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Baili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalba","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"18673_CR1","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694\u2013702. https:\/\/doi.org\/10.1200\/JCO.2005.05.188.","journal-title":"J Clin Oncol."},{"key":"18673_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA."},{"key":"18673_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol."},{"key":"18673_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. Natl Compr Canc Netw. 2024;22:331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"Natl Compr Canc Netw."},{"issue":"18","key":"18673_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000530584","volume":"2023","author":"M Balic","year":"2023","unstructured":"Balic M, Thomssen C, Gnant M, Harbeck N. St., Gallen Vienna. optimization of treatment for patients with primary breast cancer: a brief summary of the consensus discussion. Breast Care Basel. 2023;2023(18):213\u201322. https:\/\/doi.org\/10.1159\/000530584.","journal-title":"Breast Care Basel."},{"key":"18673_CR6","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1097\/SLA.0000000000004562","volume":"276","author":"G Martelli","year":"2022","unstructured":"Martelli G, Barretta F, Miceli R, et al. Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a prospective interventional study. Ann Surg. 2022;276:e544\u201352. https:\/\/doi.org\/10.1097\/SLA.0000000000004562.","journal-title":"Ann Surg."},{"key":"18673_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403\u201310. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology."},{"key":"18673_CR8","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784\u201395. https:\/\/doi.org\/10.1200\/JCO.2009.25.6529.","journal-title":"J Clin Oncol."},{"key":"18673_CR9","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"J Clin Oncol."},{"key":"18673_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","volume":"34","author":"G Curigliano","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M, et al. Understanding breast cancer complexity to improve breast cancer outcomes: the St. Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023;34:970\u201386. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.017.","journal-title":"Ann Oncol."},{"key":"18673_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","volume":"11","author":"R Yerushalmi","year":"2010","unstructured":"Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(09)70262-1.","journal-title":"Lancet Oncol."},{"key":"18673_CR12","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/sim.2174","volume":"24","author":"J Xie","year":"2005","unstructured":"Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med. 2005;24:3089\u2013110. https:\/\/doi.org\/10.1002\/sim.2174.","journal-title":"Stat Med."},{"key":"18673_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516\u201324.","journal-title":"J Am Stat Assoc."},{"key":"18673_CR14","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661\u201379.","journal-title":"Stat Med."},{"key":"18673_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/sim.4780080504","volume":"8","author":"S Durrleman","year":"1989","unstructured":"Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551\u201361.","journal-title":"Stat Med."},{"key":"18673_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up studies of failure time. Control Clin Trials. 1996;17:343\u20136. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x.","journal-title":"Control Clin Trials."},{"key":"18673_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/00031305.1986.10475403","volume":"40","author":"BK Flury","year":"1986","unstructured":"Flury BK, Reidwyl H. Standard distance in univariate and multivariate analysis. Am Stat. 1986;40:249\u201351.","journal-title":"Am Stat."},{"key":"18673_CR18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer. Ann Oncol. 2021;32:1216\u201335. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.023.","journal-title":"Ann Oncol."},{"key":"18673_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:452\u201378. https:\/\/doi.org\/10.6004\/jnccn.2020.0016.","journal-title":"J Natl Compr Canc Netw."},{"key":"18673_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamasurg.2023.1772","volume":"158","author":"S Kuemmel","year":"2023","unstructured":"Kuemmel S, Heil J, Bruzas S, et al. Safety of targeted axillary dissection after neoadjuvant therapy in patients with node-positive breast cancer. JAMA Surg. 2023;158:807\u201315. https:\/\/doi.org\/10.1001\/jamasurg.2023.1772.","journal-title":"JAMA Surg."},{"key":"18673_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/jamasurg.2014.1086","volume":"150","author":"AS Caudle","year":"2015","unstructured":"Caudle AS, Yang WT, Mittendorf EA, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. JAMA Surg. 2015;150:137\u201343. https:\/\/doi.org\/10.1001\/jamasurg.2014.1086.","journal-title":"JAMA Surg."},{"key":"18673_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/bjs.10626","volume":"105","author":"M Ahemed","year":"2018","unstructured":"Ahemed M, Douek M. Targeted axillary dissection after neoadjuvant therapy in breast cancer. Br J Surg. 2018;105:313\u20134.","journal-title":"Br J Surg."},{"key":"18673_CR23","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1001\/jamaoncol.2021.4394","volume":"7","author":"AV Barrio","year":"2021","unstructured":"Barrio AV, Montagna G, Mamtani A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy: a rare event. JAMA Oncol. 2021;7:1851\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4394.","journal-title":"JAMA Oncol."},{"key":"18673_CR24","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single-institution ten-year follow up. Eur J Surg Oncol. 2021;47:804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol."},{"key":"18673_CR25","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","volume":"27","author":"MA Piltin","year":"2020","unstructured":"Piltin MA, Hoskin TL, Day CN, Davis J Jr, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27:4795\u2013801. https:\/\/doi.org\/10.1245\/s10434-020-08900-0.","journal-title":"Ann Surg Oncol."},{"key":"18673_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/JCO.2015.64.0094","volume":"251","author":"U Veronesi","year":"2010","unstructured":"Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595\u2013600. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"Ann Surg."},{"key":"18673_CR27","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB, et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol. 2010;11:927\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2.","journal-title":"Lancet Oncol."},{"key":"18673_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa020128","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy and total mastectomy followed by irradiation. N Engl J Med. 2002;347:567\u201375.","journal-title":"N Engl J Med."},{"key":"18673_CR29","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/SLA.0b013e31827660a8","volume":"256","author":"G Martelli","year":"2012","unstructured":"Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256:920\u20134. https:\/\/doi.org\/10.1097\/SLA.0b013e31827660a8.","journal-title":"Ann Surg."},{"key":"18673_CR30","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, Stachs A, Veselinovic K, et al. Axillary surgery in breast cancer: primary results of the INSEMA trial. N Engl J Med. 2025;392:1051\u201364. https:\/\/doi.org\/10.1056\/NEJMoa2412063.","journal-title":"N Engl J Med."},{"key":"18673_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance). ACOSOG Z0011 randomized trial. Ann Surg. 2016;264:413\u201320. https:\/\/doi.org\/10.1097\/SLA.0000000000001863.","journal-title":"Ann Surg."},{"key":"18673_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel node micrometastases (IBCSG 3\u201301): a phase 3 randomized controlled trial. Lancet Oncol. 2013;14:297\u2013305. https:\/\/doi.org\/10.1016\/S1470-2045(13)70035-4.","journal-title":"Lancet Oncol."},{"key":"18673_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152:665\u201370.","journal-title":"JAMA Surg."},{"key":"18673_CR34","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with HER2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153:1120\u20136.","journal-title":"JAMA Surg."},{"key":"18673_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0207","author":"HM Kuerer","year":"2025","unstructured":"Kuerer HM, Valero V, Smith BD, et al. Exceptional Responders Study Group. Selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0207.","journal-title":"JAMA Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18673-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18673-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18673-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:40:11Z","timestamp":1770900011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18673-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18673"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18673-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Vernieri reports being a member of advisory boards for Novartis, Lilly, Pfizer, Menarini Stemline, and Daiichi Sankyo. He has received honoraria as speaker for Lilly, Novartis, Pfizer, Astra Zeneca, Menarini Stemline MSD, Istituto Gentili, and Accademia Nazionale di Medicina. Dr. Pruneri reports receiving honoraria from Lilly, Astra Zeneca, Menarini, Roche, and Illumina, and is on the Advisory Board of ADS Biotech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}